15 january

About coronavirus vaccination

About coronavirus vaccination

Following the vaccination campaign of the population against coronavirus in the Russian Federation that has been launched in December 2020, the Embassy informs that “Sputnik V” is the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform. It currently ranks among top-10 candidate vaccines approaching the end of clinical trials and the start of mass production on the World Health Organization’s (WHO) list.

The “Sputnik V” vaccine’s efficacy is confirmed at 91.4% based on data analysis of the final control point of clinical trials. The “Sputnik V” vaccine efficacy against severe cases of coronavirus is 100%.

Clinical trials of “Sputnik V” have been announced in the UAE, India, Venezuela and Belarus.

The Embassy draws special attention to the fact that only the Russian direct Investment fund (RDIF) and its manufacturing partners have the exclusive right to produce and sell the vaccine.Thus, all other organizations and individuals that distribute the vaccine do so illegally.

Requests for more than 1,2 billion doses of the “Sputnik V” vaccine came from more than 50 countries. The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.

The approximate cost of one dose of the vaccine for international markets will be less than $10 (“Sputnik V” is a two dose vaccine). The lyophilized (dry) form of the vaccine can be stored at a temperature of +2 to +8 degrees Celsius.

More detailed information can be obtained on the website: https://sputnikvaccine.com.